Elizabeth Rozek, serving as the Chief Legal and Administrative Officer at Sagimet Biosciences Inc., has completed a mandatory disposition of company equity. On July 20, 2026, Rozek sold 10,545 shares of the company's Series A Common Stock. The total proceeds from this transaction amounted to $81,832. The shares were divested at a weighted average price of $7.7603, with the specific execution prices for individual transactions ranging between $7.76 and $7.88. The transaction was classified as an automatic sale designed specifically to cover tax withholding obligations associated with the vesting of restricted stock units. Consequently, this disposition was not a discretionary decision made by Ms. Rozek. Following the completion of this transaction, her beneficial ownership position in Sagimet Biosciences Inc. Series A Common Stock stands at 224,414 shares.
This insider activity occurs against a backdrop of recent corporate financing and strategic positioning for Sagimet. The company recently announced the pricing of a $175 million stock offering intended to fund its acne drug trials. Sagimet plans to sell over 29 million shares at a price of $6.00 each. The closing of this offering is expected to occur soon, pending the satisfaction of customary conditions. This capital raise supports the company's strategic focus on developing denifanstat, an acne treatment. Sagimet intends to initiate a Phase 3 clinical trial in the United States during the second half of 2026. This upcoming trial follows successful Phase 3 results previously reported in China. The U.S. trial is contingent upon receiving Investigational New Drug clearance, with an application for this clearance scheduled for mid-2026.
Market metrics indicate significant volatility for Sagimet shares. The stock has declined 11.5% over the past week, trading at $7.05 with a market capitalization of $437 million. Analysis suggests the stock exhibits high volatility, characterized by a beta of 3.38. Despite this price fluctuation, the company maintains a strong balance sheet with more cash than debt. Investors can access additional financial metrics and analysis through the InvestingPro platform. Sagimet was recently added to the Russell 2000 and 3000 indexes, reflecting its market capitalization among the largest U.S. stocks. Analysts have adjusted their price targets for the company. Oppenheimer raised its target to $28, maintaining an Outperform rating, due to the company's focus on acne treatment. Conversely, Citizens lowered its price target to $12, while still maintaining a Market Outperform rating, citing the strategic pivot to acne treatment.